I-MAB Stock Analysis & Ratings

IMAB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$9.83 - $85.40
Previous Close$10.63
Average Volume (3M)1.18M
Market Cap$878.53M
P/E Ratio-2.2
Next EarningsSep 05, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)-4.76



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was I-MAB’s price range in the past 12 months?
I-MAB lowest stock price was $9.83 and its highest was $85.40 in the past 12 months.
    What is I-MAB’s market cap?
    I-MAB’s market cap is $878.53M.
      What is I-MAB’s price target?
      The average price target for I-MAB is $86.67. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $95.00 ,the lowest forecast is $80.00. The average price target represents 715.33% Increase from the current price of $10.63.
        What do analysts say about I-MAB?
        I-MAB’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
          When is I-MAB’s upcoming earnings report date?
          I-MAB’s upcoming earnings report date is Sep 05, 2022 which is in 102 days.
            How were I-MAB’s earnings last quarter?
            I-MAB released its earnings results on Mar 29, 2022. The company reported -$1.17 earnings per share for the quarter, missing the consensus estimate of -$0.94 by -$0.23.
              Is I-MAB overvalued?
              According to Wall Street analysts I-MAB’s price is currently Undervalued.
                Does I-MAB pay dividends?
                I-MAB does not currently pay dividends.
                What is I-MAB’s EPS estimate?
                I-MAB’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does I-MAB have?
                I-MAB has 82,650,000 shares outstanding.
                  What happened to I-MAB’s price movement after its last earnings report?
                  I-MAB reported an EPS of -$1.17 in its last earnings report, missing expectations of -$0.94. Following the earnings report the stock price went up 15.074%.
                    Which hedge fund is a major shareholder of I-MAB?
                    Among the largest hedge funds holding I-MAB’s share is Bridgewater Associates, LP. It holds I-MAB’s shares valued at 5M.


                      I-MAB Stock Analysis

                      The I-MAB stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description


                      I-Mab is a clinical stage biopharmaceutical company. It engages in discovering, developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zhang Zang on June 30, 2016 and is headquartered in Pudong, China.

                      Similar Stocks
                      Price & Change
                      Lizhi Inc
                      Arcutis Biotherapeutics
                      Revolution Medicines
                      AnPac Bio-Medical Science
                      Black Diamond Therapeutics

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis